Loss of APC function in mesenchymal cells surrounding the Müllerian duct leads to myometrial defects in adult mice

Molecular and Cellular Endocrinology

Volumn 341, Issue 1-2, 2011, Pages 48-54

  Wang, Yongyi ^a   Jia, Yundan ^a   Franken, Patrick ^a   Smits, Ron ^a   Ewing, Patricia C ^a   Lydon, John P ^b   DeMayo, Francesco J ^b   Burger, Curt W ^a   Anton Grootegoed, J ^a   Fodde, Riccardo ^a   Blok, Leen J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

APC; Endometrium; Myometrium; WNT

Indexed keywords

BETA CATENIN; SMOOTH MUSCLE ACTIN; WNT PROTEIN;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APC GENE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE INACTIVATION; GENETIC RECOMBINATION; LOSS OF FUNCTION MUTATION; MESENCHYME CELL; MOUSE; MUELLERIAN DUCT; MYOMETRIAL DEFECT; MYOMETRIUM; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TUMOR SUPPRESSOR GENE; UTERUS; UTERUS DISEASE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; BETA-GALACTOSIDASE; ENDOMETRIUM; FEMALE; GENE KNOCKOUT TECHNIQUES; GENES, REPORTER; MESODERM; MICE; MICE, INBRED C57BL; MULLERIAN DUCTS; MYOMETRIUM; PROMOTER REGIONS, GENETIC; RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 79960614742     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.026     Document Type: Article

References (33)

1. Arango N.A., Lovell-Badge R., Behringer R.R. Targeted mutagenesis of the endogenous mouse Mis gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. Cell 1999, 99:409-419.
2. Arango N.A., Szotek P.P., Manganaro T.F., Oliva E., Donahoe P.K., Teixeira J. Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev. Biol. 2005, 288:276-283.
3. Arango N.A., Kobayashi A., Wang Y., Jamin S.P., Lee H.H., Orvis G.D., Behringer R.R. A mesenchymal perspective of Mullerian duct differentiation and regression in Amhr2-lacZ mice. Mol. Reprod. Dev. 2008, 75:1154-1162.
4. Behrens J., von Kries J.P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382:638-642.
5. Bergeron C., Amant F., Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract. Res. Clin. Obstet. Gynaecol. 2006, 20:511-521.
6. Biason-Lauber A. Control of sex development. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24:163-186.
7. Dannenberg J.H., Schuijff L., Dekker M., van der Valk M., te Riele H. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev. 2004, 18:2952-2962.
8. Deutscher E., Hung-Chang Yao H. Essential roles of mesenchyme-derived beta-catenin in mouse Mullerian duct morphogenesis. Dev. Biol. 2007, 307:227-236.
9. Fodde R. The multiple functions of tumour suppressors: it's all in APC. Nat. Cell Biol. 2003, 5:190-192.
10. Fodde R., Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007, 19:150-158.
11. Fodde R., Tomlinson I. Nuclear beta-catenin expression and Wnt signalling: in defence of the dogma. J. Pathol. 2010, 221:239-241.
12. Fodde R., Edelmann W., Yang K., van Leeuwen C., Carlson C., Renault B., Breukel C., Alt E., Lipkin M., Khan P.M., et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc. Natl. Acad. Sci. USA 1994, 91:8969-8973.
13. Gaspar C., Fodde R. APC dosage effects in tumorigenesis and stem cell differentiation. Int. J. Dev. Biol. 2004, 48:377-386.
14. Jamin S.P., Arango N.A., Mishina Y., Hanks M.C., Behringer R.R. Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nat. Genet. 2002, 32:408-410.
15. Jeong J.W., Lee H.S., Franco H.L., Broaddus R.R., Taketo M.M., Tsai S.Y., Lydon J.P., DeMayo F.J. Beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus. Oncogene 2009, 28:31-40.
16. Kim K., Pang K.M., Evans M., Hay E.D. Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol. Biol. Cell 2000, 11:3509-3523.
17. Klaassens A.H., van Wijk F.H., Hanifi-Moghaddam P., Sijmons B., Ewing P.C., Ten Kate-Booij M.J., Kooi G.S., Kloosterboer H.J., Blok L.J., Burger C.W. Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestagen. Fertil. Steril. 2006, 86:352-361.
18. Klattig J., Sierig R., Kruspe D., Besenbeck B., Englert C. Wilms' tumor protein Wt1 is an activator of the anti-Mullerian hormone receptor gene Amhr2. Mol. Cell Biol. 2007, 27:4355-4364.
19. Mehasseb M.K., Bell S.C., Pringle J.H., Habiba M.A. Uterine adenomyosis is associated with ultrastructural features of altered contractility in the inner myometrium. Fertil. Steril. 2010, 93:2130-2136.
20. Mericskay M., Kitajewski J., Sassoon D. Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development 2004, 131:2061-2072.
21. Miclea R.L., Karperien M., Bosch C.A., van der Horst G., van der Valk M.A., Kobayashi T., Kronenberg H.M., Rawadi G., Akcakaya P., Lowik C.W., Fodde R., Wit J.M., Robanus-Maandag E.C. Adenomatous polyposis coli-mediated control of beta-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors. BMC Dev. Biol. 2009, 9:26.
22. Miller C., Sassoon D.A. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 1998, 125:3201-3211.
23. Molenaar M., van de Wetering M., Oosterwegel M., Peterson-Maduro J., Godsave S., Korinek V., Roose J., Destree O., Clevers H. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996, 86:391-399.
24. Moreno-Bueno G., Hardisson D., Sanchez C., Sarrio D., Cassia R., Garcia-Rostan G., Prat J., Guo M., Herman J.G., Matias-Guiu X., Esteller M., Palacios J. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002, 21:7981-7990.
25. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
26. Robanus-Maandag E.C., Koelink P.J., Breukel C., Salvatori D.C., Jagmohan-Changur S.C., Bosch C.A., Verspaget H.W., Devilee P., Fodde R., Smits R. A new conditional Apc-mutant mouse model for colorectal cancer. Carcinogenesis 2010, 31:946-952.
27. Saegusa M., Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J. Pathol. 2001, 194:59-67.
28. Scholten A.N., Creutzberg C.L., van den Broek L.J., Noordijk E.M., Smit V.T. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. J. Pathol. 2003, 201:460-465.
29. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 1999, 21:70-71.
30. Soyal S.M., Mukherjee A., Lee K.Y., Li J., Li H., DeMayo F.J., Lydon J.P. Cre-mediated recombination in cell lineages that express the progesterone receptor. Genesis 2005, 41:58-66.
31. Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998, 58:1130-1134.
32. Tanwar P.S., Lee H.J., Zhang L., Zukerberg L.R., Taketo M.M., Rueda B.R., Teixeira J.M. Constitutive activation of beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol. Reprod. 2009, 81:545-552.
33. Vainio S., Heikkila M., Kispert A., Chin N., McMahon A.P. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999, 397:405-409.